Shares of Immix Biopharma, Inc. (NASDAQ:IMMX - Get Free Report) were up 15.3% during trading on Thursday . The stock traded as high as $2.50 and last traded at $2.41. Approximately 3,883,331 shares were traded during mid-day trading, an increase of 2,729% from the average daily volume of 137,279 shares. The stock had previously closed at $2.09.
Analyst Upgrades and Downgrades
Separately, HC Wainwright restated a "buy" rating and issued a $7.00 target price on shares of Immix Biopharma in a research note on Monday, February 10th.
Read Our Latest Stock Analysis on IMMX
Immix Biopharma Trading Up 15.3%
The company has a market cap of $67.18 million, a price-to-earnings ratio of -2.84 and a beta of 0.27. The company's 50 day moving average price is $1.82 and its 200 day moving average price is $1.91.
Immix Biopharma (NASDAQ:IMMX - Get Free Report) last released its earnings results on Monday, March 24th. The company reported ($0.16) EPS for the quarter, topping the consensus estimate of ($0.25) by $0.09. Sell-side analysts predict that Immix Biopharma, Inc. will post -0.87 earnings per share for the current year.
Hedge Funds Weigh In On Immix Biopharma
An institutional investor recently bought a new position in Immix Biopharma stock. SBI Securities Co. Ltd. purchased a new stake in Immix Biopharma, Inc. (NASDAQ:IMMX - Free Report) in the fourth quarter, according to the company in its most recent filing with the SEC. The firm purchased 17,500 shares of the company's stock, valued at approximately $38,000. SBI Securities Co. Ltd. owned approximately 0.06% of Immix Biopharma as of its most recent SEC filing. 11.26% of the stock is currently owned by institutional investors and hedge funds.
Immix Biopharma Company Profile
(
Get Free Report)
Immix Biopharma, Inc, a clinical-stage biopharmaceutical company, engages in developing tissue-specific therapeutics in oncology and inflammation in the United States and Australia. The company is developing IMX-110 that is in Phase 1b/2a clinical trials for the treatment of soft tissue sarcoma and solid tumors; IMX-111, a tissue-specific biologic for the treatment of colorectal cancers; and IMX-120, a tissue-specific biologic for the treatment of ulcerative colitis and severe Crohn's disease.
Further Reading
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Immix Biopharma, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Immix Biopharma wasn't on the list.
While Immix Biopharma currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
